Progress of cyclooxygense-2 inhibitors in treatment of Alzheimer' s disease

Abstract

Abstract: Alzheimer' s disease (AD) is the most common cause of dementia in the elderly population.The occurrence of dementia correlates with inflammation.Inflammation processes may play a critical role in the pathogenesis of the degenerative changes and cognitive impairments associated with Alzheimer' s disease.Cyclooxygense- 2 (COX-2) inhibitors are reported to be effective in reducing the risk of developing AD or cognitive impairments.Studies on this field are of important significance in the understanding the pathogenesis and therapeutic measures for AD.This review will discuss the progress in the treatment of Alzheimer' s disease by COX-2 inhibitors.

Key words: pharmacology, review, cyclooxygense-2 inhibitors, nonsteroidal anti-inflammatory drugs, Alzheimer's disease

CLC Number:

R971.1
R743

SU Yuan-Qi, DONG Zhi. Progress of cyclooxygense-2 inhibitors in treatment of Alzheimer' s disease[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2003, 8(3): 249-251.

References

[1] Halliday G, Robinson SR, Shepherd C, et al.Alzheimer's disease and inflammtion:a review of cellular and therapeutic mechanisms[J]. Clin Exp Pharmacolo Physiol, 2000;27: 1-8
[2] 杨文明, 李泽庚, 周宜轩, 等.老年性痴呆病因及药物治疗[J]. 医学综述, 2002; 8:170-2
[3] Rogers J, Kirby LC, Hempelman SR, et al.Clinical trial of indomethacin in Alzheimer's disease[J]. Neurology, 1993; 43: 1609-11
[4] Bernd LF, Barbara M, Martina B, et al.Interleukin-1β induces cyclooxygenase-2 and prostaglandin E2 synthesis in human neuroblastoma cells[J]. J Neurochem, 2000;75:2020-8
[5] Wollhim FA.New function for Cox-2 in health and disease[J]. Arthritis Res, 1999; 1:45-9
[6] Raymond ND, Steven BA, Leslie C, et al.Cyclooxygenase in biology and disease[J]. FASEB J, 1998;12:1063-73
[7] Vane JR, Botting RM.Mechanism of action of nonsteroidal antiinflammatory drugs[J]. AM JMed, 1998;104: 2-8
[8] Vane J.Aspirin and other anti-inflammatory drugs[J]. Thorax, 2000; 55:3-9
[9] Aisen PS.Evaluation of selective cox-2 inhibitors for the treatment of Alzheimer's disease[J]. J Pain Symptom Manage, 2002;23:35-40
[10] Issam AM, Garret AF.Selective inhibitors of cyclooxygenase-2[J]. Mol Interventions, 2001;1:30-8
[11] Barner A.Review of clinical trials and benefit risk ratio of meloxicam[J]. Scand J Rheumatol (Suppl), 1996;102:29-31
[12] Aisen PS, Schmeidler J, Pasinetti GM, et al.Randomized pilot study of nimesulide treatment in Alzheimer's disease[J]. Neurology, 2002; 58:1050-4
[13] Hawkey CJ.COX-2 inhibitors[J]. Lancet, 1999;353: 307-14
[14] Ferencik M, Novak M, Rovensky J, et al.Alzheimer's disease, inflammation and non-steroidal anti- inflammatory drugs[J]. Bratisl Lek Lisky, 2001;102: 123-32
[15] Ehrich EW, Dallob A, Lepeleire ID, et al.Characterization of rofecoxib as a cyclooxygenase-2 isoform inhibitor and demonstration of analgesia in the dental model[J]. Clin Pharmacol Ther, 1999; 65:336-47